GO:0018119 peptidyl-cysteine S-nitrosylation

Peptidyl-cysteine S-nitrosylation (GO:0018119) is a reversible post-translational modification that involves the covalent attachment of a nitric oxide (NO) group to the thiol side chain of a cysteine residue, yielding peptidyl-S-nitrosyl-L-cysteine. This process is a central component of redox signaling and is increasingly recognized as a key regulator of protein function in health and disease. Researchers study S-nitrosylation to understand how nitric oxide modulates cellular pathways beyond classical guanylate cyclase signaling, particularly in inflammation, metabolism, and host defense. The modification can affect protein activity, subcellular localization, and protein-protein interactions, making it a critical node in signal transduction. In clinical contexts, altered S-nitrosylation patterns have been observed in metabolic and inflammatory conditions such as type 2 diabetes mellitus and periodontitis, highlighting its translational relevance. This article provides a comprehensive overview of GO:0018119, including its definition, biological significance, key genes, disease associations, and research methodologies, with a focus on CRISPR-based approaches for functional validation.

According to the Gene Ontology, peptidyl-cysteine S-nitrosylation (GO:0018119) is defined as the covalent addition of a nitric oxide (NO) group to the sulfur (S) atom of a cysteine residue in a protein, resulting in the formation of peptidyl-S-nitrosyl-L-cysteine. This modification is a biological process that occurs post-translationally and is synonymous with protein S-nitrosylation or simply S-nitrosylation. It represents a redox-sensitive regulatory mechanism where NO, often produced by nitric oxide synthases, modifies specific cysteine thiols, thereby influencing protein conformation and function.

Peptidyl-cysteine S-nitrosylation is important because it provides a reversible, redox-sensitive mechanism for regulating protein function, allowing cells to respond dynamically to nitric oxide signals. This modification is involved in a wide range of physiological processes, including vascular tone, neurotransmission, immune response, and metabolism. Dysregulation of S-nitrosylation contributes to the pathogenesis of various diseases, such as type 2 diabetes mellitus and periodontitis, where altered nitrosative stress is observed. Understanding this process at the molecular level is essential for developing targeted therapies and for interpreting proteomic data in clinical research.

The following genes and proteins are key players in peptidyl-cysteine S-nitrosylation, encompassing NO production, target modification, and denitrosylation.

S-nitrosylation is regulated by the availability of nitric oxide, the redox state of the cell, and the activity of denitrosylases such as GSNOR and thioredoxin. Additionally, the local environment of cysteine residues, including nearby acidic or basic amino acids, can influence susceptibility to S-nitrosylation. In pathological conditions like type 2 diabetes mellitus and periodontitis, altered expression of NOS enzymes and denitrosylases may contribute to dysregulated S-nitrosylation patterns.

Salivary proteomic analysis in patients with type 2 diabetes mellitus and periodontitis has revealed alterations in proteins related to nitrosative stress, suggesting that S-nitrosylation may contribute to the pathophysiology of these comorbid conditions. The study identified differential expression of proteins involved in inflammatory and metabolic pathways, highlighting the potential of S-nitrosylation as a biomarker and therapeutic target.

S-nitrosylation of proteins such as SOD1, APP, and CASP3 has been implicated in neurodegenerative diseases, including amyotrophic lateral sclerosis and Alzheimer's disease. Aberrant S-nitrosylation can lead to protein misfolding, mitochondrial dysfunction, and neuronal death.

S-nitrosylation can modulate the activity of tumor suppressors and oncoproteins, such as PTEN and TP53, influencing cell survival, proliferation, and apoptosis. Dysregulated S-nitrosylation may contribute to tumor progression and resistance to therapy.

Mass spectrometry-based proteomics, such as the biotin-switch technique coupled with LC-MS/MS, can identify S-nitrosylated proteins in biological samples. This approach has been used to detect altered S-nitrosylation in salivary samples from patients with type 2 diabetes and periodontitis.

CRISPR-Cas9 can generate knockout, point mutation, knock-in, and overexpression models to study the causal role of specific genes in S-nitrosylation. These models enable precise interrogation of gene function in disease contexts.

The biotin-switch assay and chemiluminescence-based methods can quantify S-nitrosothiol levels in cell lysates. These techniques are useful for validating findings from proteomic screens.

Genetically encoded fluorescent reporters, such as SNO-specific probes, allow real-time imaging of S-nitrosylation dynamics in live cells. These tools complement biochemical and proteomic approaches.

Researchers studying peptidyl-cysteine S-nitrosylation-related genes often need to determine whether a candidate gene is causally involved in the modification or its downstream effects. EDITGENE provides a comprehensive suite of CRISPR-based services to facilitate this research, from knockout to overexpression models, ensuring robust and reproducible results.

Peptidyl-cysteine S-nitrosylation (GO:0018119) is a critical post-translational modification that regulates protein function through nitric oxide signaling. Its involvement in diverse physiological and pathological processes, including type 2 diabetes mellitus and periodontitis, underscores its importance as a research focus. Advances in CRISPR-based models and proteomic technologies are enabling deeper insights into the mechanisms and disease relevance of S-nitrosylation. EDITGENE offers comprehensive services to support these investigations, from gene editing to bioinformatics, empowering researchers to uncover novel therapeutic targets.